Apart from variations in the expression of targetable receptors, these subtypes also exhibit differences in their immune profiles, including variations in PD-L1 expression, tumor-associated antigens, tumor mutational burden, and the quantity and composition of tumor-infiltrating lymphocytes within the tumor immune microenvironment [117]. The gene discussed is CD274; the disease is neoplasm.